URATE LOWERING EFFECT OF FEBUXOSTAT AMONG PATIENTS WITH ASYMPTOMATIC HYPERURICEMIA IN ADVANCED CHRONIC KIDNEY DISEASE: A CASE-SERIES

被引：0
|
作者：
Erika Bianca, Villazor-Isidro [1 ]
Christine Joy, Pega-Flores [1 ]
John Carlo, Brojan [1 ]
Paul, Santos-Estrella [2 ]
Jeanne, Bayaca [3 ]
机构：
[1] St Lukes Med Ctr, Dept Med, Quezon City, Philippines
[2] St Lukes Med Ctr, Rheumatol Sect, Quezon City, Philippines
[3] St Lukes Med Ctr, Nephrol Sect, Quezon City, Philippines
来源：
NEPHROLOGY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [31] Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
    Tsuruta, Yuki
    Mochizuki, Toshio
    Moriyama, Takahito
    Itabashi, Mitsuyo
    Takei, Takashi
    Tsuchiya, Ken
    Nitta, Kosaku
    CLINICAL RHEUMATOLOGY, 2014, 33 (11) : 1643 - 1648
  • [32] Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study
    Yu, Haibo
    Liu, Xinying
    Song, Yaxiang
    Cheng, Jiafen
    Bao, Hui
    Qin, Ling
    Zhou, Xuan
    Wang, Ling
    Peng, Ai
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (06) : 1324 - 1330
  • [33] Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia
    Xin Zhang
    Dapeng Wan
    Guosheng Yang
    Qingping Peng
    Xiaohui Wang
    International Urology and Nephrology, 2019, 51 : 2273 - 2283
  • [34] Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
    Liao, Zhimin
    Xu, Lei
    Wan, Bo
    Wang, Liping
    Zhao, Chengzhi
    Wu, Gang
    Xie, Rui
    EMERGENCY MEDICINE INTERNATIONAL, 2022, 2022
  • [35] Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia
    Zhang, Xin
    Wan, Dapeng
    Yang, Guosheng
    Peng, Qingping
    Wang, Xiaohui
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (12) : 2273 - 2283
  • [36] Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
    Yuki Tsuruta
    Toshio Mochizuki
    Takahito Moriyama
    Mitsuyo Itabashi
    Takashi Takei
    Ken Tsuchiya
    Kosaku Nitta
    Clinical Rheumatology, 2014, 33 : 1643 - 1648
  • [37] Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia
    Takata, Tomoaki
    Taniguchi, Sosuke
    Mae, Yukari
    Kageyama, Kana
    Fujino, Yudai
    Iyama, Takuji
    Hikita, Katsuya
    Sugihara, Takaaki
    Isomoto, Hajime
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [38] Effect of urate-lowering therapy on renalfunction in chronic kidney disease stages 2-5 pa-tients with hyperuricemia
    祖爽
    ChinaMedicalAbstracts(InternalMedicine), 2018, 35 (04) : 229 - 230
  • [39] Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis
    Kim, Sang-Hyon
    Lee, So-Yeon
    Kim, Ji-Min
    Son, Chang-Nam
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (04): : 998 - 1003
  • [40] Association between urate-lowering therapy and kidney failure in patients with chronic kidney disease
    Mouheb, Agathe
    Lambert, Oriane
    de Pinho, Natalia Alencar
    Jacquelinet, Christian
    Laville, Maurice
    Combe, Christian
    Fouque, Denis
    Frimat, Luc
    Massy, Ziad A.
    Laville, Solene M.
    Liabeuf, Sophie
    JOURNAL OF NEPHROLOGY, 2025, : 597 - 607
12345